4.8 Article

American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal Definition of Myocardial Infarction Classification System and the Risk of Cardiovascular Death Observations From the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)

期刊

CIRCULATION
卷 125, 期 4, 页码 577-U90

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.111.041160

关键词

myocardial infarction; mortality; outcomes

资金

  1. Abbott Laboratories
  2. Accumetrics
  3. Amgen
  4. AstraZeneca
  5. Beckman Coulter
  6. Bristol-Myers Squibb
  7. CV Therapeutics
  8. Daiichi Sankyo Co Ltd
  9. Eli Lilly and Co
  10. GlaxoSmithKline
  11. Integrated Therapeutics
  12. Merck and Co
  13. Nanosphere
  14. Novartis Pharmaceuticals
  15. Nuvelo
  16. Ortho-Clinical Diagnostics
  17. Pfizer
  18. Roche Diagnostics
  19. sanofi-aventis
  20. Sanofi-Synthelabo
  21. Siemens Medical Solutions
  22. Singulex
  23. Cardiokinetix
  24. Gilead
  25. Instrumentation Laboratory
  26. Ikaria
  27. Merck
  28. Ortho Clinical Diagnostics
  29. Siemens

向作者/读者索取更多资源

Background-The availability of more sensitive biomarkers of myonecrosis and a new classification system from the universal definition of myocardial infarction (MI) have led to evolution of the classification of MI. The prognostic implications of MI defined in the current era have not been well described. Methods and Results-We investigated the association between new or recurrent MI by subtype according to the European Society of Cardiology/American College of Cardiology/American Heart Association/World Health Federation Task Force for the Redefinition of MI Classification System and the risk of cardiovascular death among 13 608 patients with acute coronary syndrome in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). The adjusted risk of cardiovascular death was evaluated by landmark analysis starting at the time of the MI through 180 days after the event. Patients who experienced an MI during follow-up had a higher risk of cardiovascular death at 6 months than patients without an MI (6.5% versus 1.3%, P<0.001). This higher risk was present across all subtypes of MI, including type 4a (peri-percutaneous coronary intervention, 3.2%; P<0.001) and type 4b (stent thrombosis, 15.4%; P<0.001). After adjustment for important clinical covariates, the occurrence of any MI was associated with a 5-fold higher risk of death at 6 months (95% confidence interval 3.8-7.1), with similarly increased risk across subtypes. Conclusions-MI is associated with a significantly increased risk of cardiovascular death, with a consistent relationship across all types as defined by the universal classification system. These findings underscore the clinical relevance of these events and the importance of therapies aimed at preventing MI.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据